MENU

FIND DOCTORS

Name: Guo Lin
Department: CLINICAL LABORATORY
Title:Senior Technologist

 
 
 
Education & Professional Experience    2012.1-Present: Senior Technologist, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center/Department of Oncology, Fudan University Shanghai Cancer Center.
2011.9-Present: Supervisor of Master graduate, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center/Department of Oncology, Fudan University Shanghai Cancer Center. 
2004.9-Present, MS, Major: Laboratory Medicine, Fudan University Shanghai Medical School. 
1999.7-2012.1: Associate Senior Technologist, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center /Department of Oncology, Fudan University Shanghai Cancer Center.
1984.9-1988.6, BS, Major: Laboratory Medicine, Department of Laboratory Medicine, Shanghai Medical University. 
 
 
Specialty   Member of Laboratory medicine branch of Shanghai Medical Association; Member of Chinese Clinical Immunology Committee; Member of Immunotechnology Committee of Shanghai Municipality; Editorial board member of China Oncology, Laboratory Medicine, anticancer, Chinese journal of clinical physician.
 
 
Research   Clinical Immunology
 
 
Publication   1. Lu RQ, Wu CS, Guo L, Liu YC, Mo W, Wang HJ, Ding JB, Wong ET, Yu M. The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo. BMC Cancer 2012; 12: 607.
2. Lu RQ, Sun XH, Xiao R, Zhou L, Gao X, Guo L*,. Human Epididymis Protein 4 (HE4) Plays a Key Role in Ovarian Cancer Cell Adhesion and Motility. Biochemical Biophysical Research Communications 2012; 419(2): 274-280. (corresponding author)
3. Lu RQ, Yang DP, Cui DX, Guo L*. Egg-white mediated Green synthesis of Silver Nanoparticles with excellent biocompatibility and Enhanced Radiation Effects on Cancer Cells. International Journal of Nanomedicine 2012; 7: 2101-2107. (corresponding author)
4. Lu RQ, Dou XW, Gao X, Zhang J, Ni J, Guo L*. A functional polymorphism of lymphotoxin-alpha (LTA) gene rs909253 is associated with gastric cancer risk in an Asian population. Cancer Epidemiology 2012; 36(6): e380-386. (corresponding author)
5. Lu RQ, Gao X, Chen Y, Li S, Ni J, Guo L*. Association of an NF-kappaB1 intron SNP (rs4648068) with gastric cancer patients in Chinese Han population. BMC gastroenterology 2012; 12: 87. (corresponding author)
6. Wang M, Jiang ML, Jiang R, Guo L *. Application value of monitoring D-dimer for perioperative ovarian cancer patients , China Oncology,22(5):381-384, 2012. (corresponding author)
7. Hu J, Guo L*. Clinical application of serum marker HE4 in diagnosis and treatment of endometrial cancer. Current Immunology,2012,32(2):64-167. (corresponding author)
8. Lu RQ, Sun M, Feng JJ, Gao X, Guo L*. Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer, BMC Cancer 2011, 11: 270. (corresponding author)
9. Shen YH, Lu RQ, Guo L. Clinical Value of Urinary Iodine Determination in Screening for Thyroid Tumor. China Cancer 2011, 20(9): 699-702.
10. Xiao CL, Tao ZH, Guo L*, Li WW, Wan JL, Sun HC, Wang L, Tang ZY, Fan J and Wu WZ. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice, BMC Cancer, 11:150, 2011.
11. Lu RQ, Guo L*, Shen YH. The value of human epididymis protein 4 in patients with ovarian cancer. China Oncology 2010, 20(9): 585- 590. (corresponding author)
12. Lu RQ, Hu J,Guo L*. Studier on the value of human epididymis protein 4 in patients with ovarian cancer. Chinese Journal Laboratory Medicine 2009, 32(12): 1379-1383 (corresponding author)
13. Lu RQ, Zheng ZY,Guo L*. Development of a gold immunochromatographic assay reagent for rapid detection of alpha-fetoprotein and carcinoembryonic antigen and evaluation of its performance. Laboratory Medicine 2009, 24(12): 899- 903. (corresponding author)
14. Lu RQ, Xu XF,Guo L*. Clinical value of plasma tumor type M2 pyruvate kinase determination in patients with gastrointestinal cancer. Laboratory Medicine 2008, 23(4): 370- 373. (corresponding author)
15. Lu RQ, Xu XF,Guo L*. Diagnostic value of tumor type M2 pyruvate kinase in patients with breast cancer。Chinese Journal Laboratory Medicine 2008, 31(8): 884- 886. (corresponding author)
Patents: 2012; “Development of the kit for human plasma tumor type-M2 pyruvate kinase concentration and its preparation” Authorized No.: ZL 2008 1 0033501.4.
 
 
Awards   2012 “Excellent Supervisor of Master” Fudan University Shanghai Cancer Center;
2012 “Establishment of the immunoassay for human plasma MR-1 concentration and its preparation” [Excellent Invention, Silver Award]; The Excellent Invention competetion Commission of Shanghai Municipality;
2009 “Development of the kit for human plasma tumor type-M2 pyruvate kinase concentration and its preparation” [Excellent Invention, Bronze Award]; The Excellent Invention competetion Commission of Shanghai Municipality